Amarantus Exercises Exclusive Option with
Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test
2.0"
- Scope of exercised Exclusive
Option Agreement
expanded to include negotiations
for IP rights
to additional key markers
collected in German
clinical study, including CSF-tau
New York, NY -- May 30,
2018 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings,
Inc. (OTC
Pink: AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus
biotechnology holding company, developing first-in-class orphan
neurologic, regenerative medicine and ophthalmic therapies and
diagnostics through its subsidiaries, today announced that based
upon its review of the clinical data from a German-based clinical
study led by Leipzig University's (Leipzig) Dr. Thomas Arendt, the
Company has exercised its Exclusive Option with Leipzig to
negotiate license rights to Alzheimer's blood diagnostic "LymPro
Test 2.0," which compares traditional LymPro Test results with
those of amyloid PET imaging for the diagnosis of Alzheimer's
disease. Amarantus and Leipzig have agreed to expand the scope of
license negotiations to include additional key markers collected
during the clinical study, including CSF-tau.
"LymPro holds significant
promise as a solution to one of the key areas of Alzheimer's
research: the use of a blood-based biomarker for the early
detection of Alzheimer's, either at the pre-symptomatic stage or
mild cognitive impairment stage, in patients likely to progress to
full dementia of the Alzheimer's-type," said Dr. Michael Ropacki,
Chief Medical Advisor for LymPro.
Leipzig University has
completed a clinical study comparing LymPro's ability to
distinguish dementia of the Alzheimer's-type from other types of
dementia, as diagnosed using clinical assessments and biological
markers (including amyloid PET imaging and CSF-tau). Upon closing a
final license agreement for Leipzig's IP Rights related to LymPro
Test 2.0, as well as related collaboration agreements, Amarantus
will collaborate with Leipzig on a confirmatory clinical study that
is already enrolling in Germany under Dr. Arendt's
supervision.
AAIC 2015
Poster Presentation of LymPro Test LP-002 Clinical
Data
Amarantus
Alzheimer's Diagnostics Scientific Advisory
Board
LymPro
Test CLIA Validation complete
Dr. Ropacki
Appointed Chief Medical Advisor for Alzheimer's Blood Diagnostic
LymPro Test
About Alzheimer's
Disease
According to the
Alzheimer's Association, it is estimated that over 5.4 million
people in the United States suffer from Alzheimer's disease. Over
500,000 patients are diagnosed annually, with nearly one-in-eight
older Americans affected by the disease. Alzheimer's disease is the
third leading cause of death in the United States. The cost of
unpaid care in the United States is estimated at over $210 billion
annually. Total payments for care are estimated at over $200
billion annually, including $140 billion in cost to Medicare and
Medicaid. Alzheimer's expenditures in the United States are
expected to exceed $1.2 trillion by 2050. There is no cure or
effective treatment for Alzheimer's disease. Worldwide, about 35.6
million individuals have the disease and, according to the World
Health Organization, the number will double every 20 years to 115.4
million people with Alzheimer's by 2050.
About Dr.
Arendt's Research at Leipzig
University
Dr. Thomas Arendt is
Professor of Neuroscience at Leipzig University where he runs the
Paul Flechsig Institute of Brain Research. He has a 30-year record
in R&D of therapeutic and diagnostic strategies of
neurodegenerative disorders and made several seminal contributions
to therapeutic concepts of Alzheimer's disease, including stem cell
therapy and modulating tumor suppressor genes. In the early 1980's,
he was involved in identifying the degeneration of the cholinergic
system in Alzheimer's disease laying the basis for today's only
available treatment. He is one of the pioneers of the "cell-cycle
theory" of Alzheimer's disease, which he developed towards a
diagnostic and therapeutic concept.
About LymPro
Test
The Lymphocyte
Proliferation Test (LymPro Test) is a diagnostic blood test that
determines the ability of peripheral blood lymphocytes (PBLs) and
monocytes to withstand an exogenous mitogenic stimulation that
induces them to enter the cell cycle. It is believed that certain
diseases, most notably Alzheimer's disease, are the result of
compromised cellular machinery that leads to aberrant cell cycle
re-entry by neurons which then leads to apoptosis. LymPro is unique
in the use of peripheral blood lymphocytes as a surrogate for
neuronal cell function, suggesting a common relationship between
PBLs and neurons in the brain.
About Amarantus
Bioscience Holdings, Inc.
Amarantus Bioscience
Holdings (AMBS) is a JLABS alumnus biotechnology company developing
treatments and diagnostics for diseases in the areas of neurology,
regenerative medicine and orphan diseases through its subsidiaries.
AMBS' wholly-owned subsidiary Elto Pharma, Inc. has
development rights to eltoprazine, a Phase 2b-ready small molecule
indicated for Parkinson's disease levodopa-induced dyskinesia,
Alzheimer's aggression and adult attention deficit hyperactivity
disorder, commonly known as ADHD. AMBS acquired the rights to the
Engineered Skin Substitute program, a regenerative medicine-based
approach for treating severe burns with full-thickness autologous
skin grown in tissue culture that is being pursued by AMBS'
wholly-owned subsidiary Cutanogen Corporation. AMBS'
wholly-owned subsidiary MANF Therapeutics, Inc. owns key
intellectual property rights and licenses from a number of
prominent universities related to the development of the
therapeutic protein known as mesencephalic astrocyte-derived
neurotrophic factor ("MANF"). MANF Therapeutics, Inc.
is developing MANF-based products as treatments for brain and
ophthalmic disorders. MANF was discovered by the Company's Chief
Scientific Officer John Commissiong, PhD. Dr. Commissiong
discovered MANF from AMBS' proprietary discovery engine PhenoGuard.
The Company also re-acquired rights to the Alzheimer's blood
diagnostic LymPro Test , MSPrecise and NuroPro.
For further information
please visit www.Amarantus.com, or connect with the Amarantus on Facebook,LinkedIn,Twitterand Google+.
Amarantus
Investor and Media Contact:
Howard
Gostfrand
American Capital Ventures,
Inc.
Office:
305-918-7000
Email: hg@amcapventures.com
Source: Amarantus
Bioscience Holdings, Inc.